专栏名称: 华人抗体
华人抗体协会 (Chinese Antibody Society). 使命和愿景 两个一:第一个“一”是中国抗体药走向世界的桥梁; 第二个“一”是中美乃至全球抗体领域华人交流合作的平台。两个侧重:侧重于治疗性抗体药; 侧重于中国。
目录
相关文章推荐
天津日报  ·  致3人受伤、5车受损,成都警方通报→ ·  14 小时前  
天津日报  ·  真相大反转!系摆拍 ·  昨天  
生态梦网  ·  生态城这个片区社区中心暂无建设计划 ·  2 天前  
生态梦网  ·  最新!生态城这个区域规划调整获批 ·  2 天前  
51好读  ›  专栏  ›  华人抗体

华人抗体协会Webinar第七十二讲:TIL疗法在实体瘤中的突破与发展

华人抗体  · 公众号  ·  · 2023-11-23 08:39

正文

请到「今天看啥」查看全文



Yarong Liu, Ph.D., Founder and CEO at Grit Therapeutics, Visiting Professor at Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Science and Technology Leader of Suzhou Industrial Park, Gusu Leader, Expert of Shanghai Thousand Talents Program, Shanghai Pujiang Talent, Principal Investigator, member of CSCO, member of China Medical Women's Association, and member of Pudong New Area Youth Federation. Over 10 years of experience in AAV, LVV and other viral vectors for targeted gene therapy and experience in LVV industrial-grade manufacturing. She has published more than 40 papers in top international journals such as Nature Communications, Science Immunology, Gene Therapy, and Molecular Therapy. She holds one U.S. technology patent and more than 80 invention patent applications. She is in charge of a biompharmaceutical science and technology support project of Shanghai, and participates in the national major new drug development project. She won the third prize of Pudong New Area Science and Technology Progress Award for startup team in 2017 as the second person-in-charge, Shanghai New Entrepreneur award and silver award of Yangtze River Delta Women's Innovation and Startup Competition in 2021, and Pudong Outstanding Young Entrepreneur in 2022. In 2019, she founded Grit Biotechnology, which is dedicated to R&D and clinical application of innovative TIL therapy for solid tumor treatment.



本期讲座

题目 TIL疗法在实体瘤中的突破与发展

摘要 :本次讲座将围绕四个要点展开:TIL与其他细胞治疗相比在实体瘤治疗中的独特优势,近年来TIL疗法在多种实体瘤中的临床进展,沙砾生物推进TIL疗法临床转化和下一代TIL探索和开发的历程以及TIL疗法的发展方向展望。

Title :Progress and Breakthroughs of TIL therapy in Solid Tumors

Abstract This lecture will revolve around four key points: the unique advantages of TIL in the treatment of solid tumors compared with other cell therapies; clinical progress of TIL therapy in treatment of different types of solid tumors in recent years; Grit Bio's efforts on promoting the clinical translation of TIL therapy and developing next-generation TIL products and prospective of the future directions of TIL therapy.

(扫描二维码 注册Webinar)

友情提醒

  • 我可以最后一分钟注册讲座吗? 请尽量至少提前一天注册

  • 我注册成功了吗? 注册成功后会收到确认邮件,邮件含有当日连入webinar的链接,点击链接即可顺利进入webinar

  • 我没有收到邮件? 检查一下您的自动过滤邮箱

  • 我用什么软件参加讲座? 讲座使用Zoom平台,PC,苹果和安卓系统都可以下载







请到「今天看啥」查看全文